In an immunocompetent murine model of orthotopic ATC, treatment with BRAF inhibitor PLX4720 alone, in combination with anti-PD-1, or with anti-PD-L1 antibody, led to significant tumor reduction of 41%, 61%, and 64%, respectively. This evidence concerns the gene CD274 and neoplasm.